VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZNTL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZNTLZentalis Pharmaceuticals, Inc.
$1.36$97M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ZNTL logo

Zentalis Pharmaceuticals, Inc.

ZNTL
NASDAQ · Oncology Biotech
$1.36
At close - Nov 18, 4:00 PM EST - USD
Market Cap$97M
P/E-0.8x
52W High$6.95
Volume1.21M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Cash Burn Accelerates as Zentalis Runway Narrows Sharply

Zentalis shows no reported revenue in recent quarters while operating losses widened to -$82.2M in 2026Q2 driven by R&D rising to $63.9M, suggesting R&D spend is outpacing any commercial offset.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ZNTL price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-103% Peers

P/E is 103% below peer median

03

Market leadership

RS 17 · Lag

Laggard (Underperforming 83% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 9

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ZNTL-0.73%
S&P 500 (^GSPC)+6.88%
1-Year Return
ZNTL+0.00%
S&P 500 (^GSPC)+10.62%
3-Year Return
ZNTL-87.43%
S&P 500 (^GSPC)+57.75%
5-Year Return
ZNTL-98.28%
S&P 500 (^GSPC)+50.02%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$137M+17.4% YoY
Free cash flow FY25
-$125M+26.8% YoY
Operating margin FY25
-
ROIC (FY25)-40.5%
Avg ROIC 5Y-44.3%
ROE (TTM)-75.8%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate1/12 (100%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 9, 2026
-$0.34+37.3%
vs -$0.54
—
vs —
Q3 2026
Aug 6, 2026
-$0.59-20.4%
vs -$0.49
—
vs —
Q2 2026
May 12, 2026
-$0.50-2.0%
vs -$0.49
—
vs —
Q2 2026
Mar 26, 2026
-$0.49-19.5%
vs -$0.41
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 9, 2026
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROC DENALI Part 2c enrollment scheduled to complete in November 2026, with an integrated topline readout expected in 1H 2027 $228.9 million in cash, cash equivalents and marketable securities as of September 30, 2026 provides runway into 1H 2028 to support execution of key milestones SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent business updates. "Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved," said Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals.

GlobeNewsWire·Nov 3, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:

GlobeNewsWire·Nov 2, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on November 2, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 136,000 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire·Oct 23, 2026
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Filtered for Zentalis Pharmaceuticals, Inc.More Headlines
04

Compare before deciding

Benchmark ZNTL against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Zentalis Pharmaceuticals, Inc. (ZNTL)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ZNTL logoZNTLZentalis Pharmaceuticals, Inc.Current
$1.36$96.81M-0.81-100%—-75.82%—
RVMD logoRVMDRevolution Medicines, Inc.
$159.82$33.98B-18.37—-946.82%-91.93%—
KYMR logoKYMRKymera Therapeutics, Inc.
$121.13$9.96B-34.69-16.72%-341.87%-22.39%—
AUPH logoAUPHAurinia Pharmaceuticals Inc.
$15.13$1.95B6.5120.38%97.68%51.92%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.19$8.51B-24.78-100%—-29.41%—
TGTX logoTGTXTG Therapeutics, Inc.
$66.12$10.12B97.2187.32%11.81%17.62%—

Compare ZNTL vs Peers

Zentalis Pharmaceuticals, Inc. (ZNTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RVMD

Most directly comparable listed peer for ZNTL.

Scale Benchmark

vs IQV

Larger-name benchmark to compare ZNTL against a more recognizable public peer.

Peer Set

Compare Top 5

vs RVMD, KYMR, AUPH, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ZNTL SEC Filings & Documents

Zentalis Pharmaceuticals, Inc. (ZNTL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jun 18, 2026·SEC

Material company update

May 27, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 26, 2026·SEC

FY 2025

Mar 26, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 6, 2026·SEC

FY 2026

May 12, 2026·SEC

FY 2025

Nov 10, 2025·SEC

Get notified when ZNTL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ZNTL Frequently Asked Questions

Zentalis Pharmaceuticals, Inc. (ZNTL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
How fast is Zentalis Pharmaceuticals, Inc. growing?

Zentalis Pharmaceuticals, Inc. (ZNTL) revenue fell by 100.0% over the trailing twelve months, compared with the twelve months before.

Is ZNTL profitable?

No. Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $141.7M over the trailing twelve months.

Dividend & Returns
What is ZNTL's return on equity?

Zentalis Pharmaceuticals, Inc. (ZNTL) had a return on equity (ROE) of -75.8% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Zentalis Pharmaceuticals, Inc.'s free cash flow?

Zentalis Pharmaceuticals, Inc. (ZNTL) had negative free cash flow of $166.9M over the trailing twelve months.

What if you invested $1,000 in ZNTL back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →